Sacubitril/valsartan (LCZ696) for the treatment of heart failure [0.03%]
用于治疗心力衰竭的sacubitril/缬沙坦(LCZ696)
Mauro Gori,Michele Senni
Mauro Gori
The PARADIGM-HF study, a large outcome trial in heart failure and reduced ejection fraction (HFrEF), has recently shown improved cardiovascular outcomes with sacubitril/valsartan (Entresto®, Novartis), still commonly referred to as LCZ696,...
A focus on inflammation as a major risk factor for atherosclerotic cardiovascular diseases [0.03%]
炎症：动脉粥样硬化性心血管疾病的主要危险因素
Ida Gregersen,Sverre Holm,Tuva B Dahl et al.
Ida Gregersen et al.
Atherosclerosis is a dynamic, pathogenic process in the artery wall, with potential adverse outcome for the host. Acute events such as myocardial infarction and ischemic stroke often result from rupture of unstable atherosclerotic lesions. ...
Neil J Stone,Alexander Turin,Jared A Spitz et al.
Neil J Stone et al.
This review provides needed perspective on statin efficacy and safety in individuals under 40, 40-75, and > 75 years of age. Starting with the 2013 ACC-AHA cholesterol guidelines extensive evidence base on randomized controlled trials (RCTs...
Can the sum of pooled data from observational studies better evaluate outcome measures for therapies in coronary artery disease? [0.03%]
观察性研究的汇总数据能否更好地评估冠心病治疗的效果指标？
Suvitesh Luthra,David P Taggart
Suvitesh Luthra
Randomized control trials (RCTs) are considered the gold standard in the hierarchy of evidence based medicine. Guidelines and recommendations for clinical practice are based on the strength of evidence in this hierarchical tree. This articl...
Clinical management of dilated cardiomyopathy: current knowledge and future perspectives [0.03%]
扩张型心肌病的临床管理：现状与未来展望
Marco Merlo,Antonio Cannatá,Alice Vitagliano et al.
Marco Merlo et al.
Dilated cardiomyopathy (DCM) is a primary heart muscle disease characterized by a progressive dilation and dysfunction of either the left or both ventricles. The management of DCM is currently challenging for clinicians. The persistent lack...
Antithrombotic therapy following transcatheter aortic valve implantation: what challenge do we face? [0.03%]
经导管主动脉瓣植入术后的抗栓治疗：我们面临哪些挑战？
Marco Barbanti,Simona Gulino,Corrado Tamburino et al.
Marco Barbanti et al.
The issue of stroke and bleeding events following transcatheter aortic valve implantation (TAVI) and its relation with antithrombotic regimens before, during and after the procedure is increasingly recognized as an important issue. While de...
Developments in surgical revascularization to achieve improved morbidity and mortality [0.03%]
外科手术血管重建的进展以达到更好的伤残率和死亡率
Amir H Sepehripour,Thanos Athanasiou
Amir H Sepehripour
Coronary artery bypass graft surgery remains the main treatment modality for multivessel coronary artery disease and has consistently been demonstrated to have significantly lower rates of major adverse cardiac and cerebrovascular events in...
Sylvie Di Filippo
Sylvie Di Filippo
Acute viral myocarditis may impair prognosis in children of all ages. Its true incidence is underestimated because of heterogeneity of presentation and outcome. Patients may either recover or progress to chronic cardiomyopathy or death. Imp...
Catheter-directed thrombolysis for extensive iliofemoral deep vein thrombosis: review of literature and ongoing trials [0.03%]
腔内溶栓治疗髂股静脉血栓形成进展及临床研究展望
Aaron Liew,James Douketis
Aaron Liew
In patients with extensive lower limb deep vein thrombosis (DVT) that, typically, extends into the iliofemoral veins, catheter-directed thrombolysis (CDT) can achieve faster and more complete thrombus lysis as compared with systemic thrombo...
The role of imaging in the diagnosis and management of hypertrophic cardiomyopathy [0.03%]
影像在肥厚型心肌病诊断和治疗中的作用
Adaya Weissler-Snir,Andrew Crean,Harry Rakowski
Adaya Weissler-Snir
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy, affecting approximately 1:500 people. As the yield of genetic testing is only about 35-60%, the diagnosis of HCM is still clinical and based on the demonstration o...